跳转至内容
Merck
CN
所有图片(1)

主要文件

371R-1

Sigma-Aldrich

SOX-2 (SP76) Rabbit Monoclonal Antibody

登录查看公司和协议定价


About This Item

UNSPSC代码:
12352203
NACRES:
NA.41

生物来源

rabbit

质量水平

偶联物

unconjugated

抗体形式

culture supernatant

抗体产品类型

primary antibodies

克隆

SP76, monoclonal

描述

For In Vitro Diagnostic Use in Select Regions (See Chart)

表单

buffered aqueous solution

种属反应性

human

包装

vial of 0.1 mL concentrate (371R-14)
vial of 0.5 mL concentrate (371R-15)
bottle of 1.0 mL predilute (371R-17)
vial of 1.0 mL concentrate (371R-16)
bottle of 7.0 mL predilute (371R-18)

制造商/商品名称

Cell Marque®

技术

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:50-1:200

同位素/亚型

IgG

控制

squamous epithelium

运输

wet ice

储存温度

2-8°C

可视化

nuclear

基因信息

human ... SOX2(6657)

一般描述

It has been reported that anti-SOX-2 antibody recognizes lung squamous cell carcinoma (LSCC). A recent study has demonstrated that extensive anti-SOX-2 staining was seen in over 90% of LSCC and largely paralleled p63 expression. Extensive anti-SOX-2 staining was seen in 21% of lung adenocarcinomas (LACA), including cases that were anti-p63-negative or only anti-p63 focally-positive. However, another recent study showed only 4.5% of LACA is positive for anti-SOX-2 expression. In a study by Sholl et al, 29% of LACA cases exhibited at least focal p63 expression. Combined p63 and SOX-2 expression was seen in 94% of LSCC and 12% of LACA with a statistically significant difference (P<0.0001) versus p63 alone. This study also showed that anti-CK5/6 had a good sensitivity but poor specificity for LSCC. Combined anti-CK5/6 and anti-p63 positivity was seen in 93% of LSCC and 24% of LACA. Anti-CK5/6+/anti-p63+/anti- SOX-2+ was detected in 93% of LSCC and only 9% of LACA. These results indicate that the sensitivity of anti-p63 is equally high but its specificity is similarly variable; it was seen at least focally in close to 30% of LACA. When used together, anti-p63+/anti-SOX-2+ applied to the same tumor cell population is >90% specific for LSCC. Anti-SOX-2 produced moderate-to-intense staining in all 50 cases of embryonal carcinoma components. The only other component that showed reactivity was the primitive neuroectodermal component in 11 of 14 (79%) of immature teratomas. In each of these positive staining foci, the staining varied from moderate-to-strong. Yolk sac tumor, seminoma, mature teratoma, choriocarcinoma, and IGCNU were uniformly negative, as were all the non-neoplastic parenchymal and stromal structures.

质量


IVD

IVD

IVD

RUO

联系

SOX-2 Positive Control Slides, Product No. 371S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).

外形

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide

制备说明

Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.

其他说明

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

法律信息

Cell Marque is a registered trademark of Merck KGaA, Darmstadt, Germany

未找到合适的产品?  

试试我们的产品选型工具.


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持